AUTHORS
Francesco Autore, MD, Annamaria Frustaci, MD2, Giulia Benevolo, MD3, Nicolò Danesin, MD4, Diana Giannarelli5, Rita Rizzi6, Maura Nicolosi, MD7, Emanuele Cencini8, Raffaella Pasquale9, Concetta Conticello, MD10, Sara Steffanoni11, Martina Bullo12, Dario Marino, MD, PhD13, Massimo Gentile14, Idanna Innocenti, MD, PhD15, Luca Stirparo16, Annamaria Tomasso17, Giorgia D'Uva18, Francesco Piazza, MD19, Alessandra Tedeschi20, Luca Laurenti Sr, MD21
AFFILIATIONS
1 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
2 Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
3 Ematologia Universitaria A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
4 Hematology Unit, Department of Medicine, University of Padova, Padova, Italy, Pdova, Italy
5 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
6 Università degli Studi 'Aldo Moro,' A.O.U. Consorziale Policlinico di Bari, Bari, Italy
7 SC Ematologia, AOU Città della Salute e della Scienza,, Torino, Italy
8 A.O.U. Senese e Università di Siena,, Siena, Italy
9 Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
10 Divisione di Ematologia e Trapianto di Midollo Osseo, Policlinico Gaspare Rodolico di Catania, Catania, Italy
11 Centro Valduce di Como, Como, Italy
12 Ordine Mauriziano di Torino, Torino, Italy
13 Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
14 Azienda Ospedaliera di Cosenza, Cosenza, Italy
15 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
16 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
17 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
18 Ematologia Universitaria A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
19 Hematology Unit, Department of Medicine, University of Padova, Padova, Italy, Pdova, Italy
20 Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
21 Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
ABSTRACT
Infections are a major cause of morbidity and mortality in patients with Waldenström Macroglobulinemia (WM). Over recent years, the use of Bruton’s Tyrosine Kinase inhibitors (BTKis) has increased in WM, with the perception of reduced infection rates. However, available data are largely derived from clinical trials, and real-world evidence remains scarce.
This study aimed to describe infectious complications in patients with WM treated with chemo-immunotherapy (CIT) or BTKis in a real-world setting, evaluating infection incidence during first- and second-line treatment according to the timing of onset.
This retrospective multicentre study included 496 patients diagnosed with WM and treated since 2008 across 13 Italian hematology centres.
In the first-line setting, treatments included bendamustine-rituximab (BR, n=169), dexamethasone-rituximab-cyclophosphamide (DRC, n=150), other CIT regimens (n=62), rituximab or steroids alone (n=54), chemotherapy alone (n=40), and BTKis (n=21). A total of 116 infections were recorded. Infection rates at 0–6, 6–12, 12–18, and 18–24 months were: BR 16%/5%/3%/3%, DRC 10%/3%/1%/0%, and BTKis 5%/7%/0%/0%. Thirty-five infections (30.2%) required hospitalization, with rates of BR 6%/2%/1%/1%, DRC 1%/1%/0%/0%, and BTKis 0%/0%/0%/0%.
In the second-line setting, 214 patients received subsequent therapies: BTKis (n=111), BR (n=24), DRC (n=15), bortezomib-based regimens (n=20), chemotherapy (n=24), and rituximab alone (n=20). A total of 76 infections were observed. Infection rates at 0–6, 6–12, 12–18, and 18–24 months were: BR 17%/5%/5%/0%, DRC 0%/0%/0%/0%, and BTKis 10%/7%/13%/2%. Twenty-six infections (34.2%) resulted in hospitalization, with rates of BR 12%/0%/5%/0%, DRC 0%/0%/0%/0%, and BTKis 3%/3%/2%/0%.
Overall, infection rates were similar between first- and second-line treatment within each regimen, except BTKis. In first line, BTKis were associated with lower infection rates than BR and DRC during the first 6 months, similar rates between 6 and 12 months, and no infections beyond 12 months. No infection-related hospitalizations occurred with BTKis, whereas hospitalization rates remained low with BR (except during the first 6 months, 6%) and DRC. Among CIT regimens, DRC showed the lowest infection rates, with no infectious events in second line. In relapsed/refractory WM, BR showed higher infection rates than BTKis during the first 6 months, whereas BTKis had higher rates between 6–12 and 12–18 months. Hospitalization rates remained low with both regimens, except for BR during the first 6 months (12%).
This large retrospective real-world study highlights the favourable infectious safety profile of BTKis, particularly in the first-line setting, where they were associated with numerically lower infection rates without infection-related hospitalizations in this retrospective cohort. Among CIT regimens, DRC also emerged as a well-tolerated alternative with a low risk of infectious complications. In relapsed/refractory WM, infections remained infrequent but were more common during the first 18 months of BTKi therapy, supporting closer monitoring and appropriate prophylaxis during this period. These findings support BTKis as a preferred frontline strategy from an infectious safety perspective. Future studies should determine whether earlier use of BTKis and fixed-duration BTKi-based combinations can maintain the favourable infectious profile observed with continuous BTKi therapy in second-line.
DISCLOSURES
Francesco Autore, MD: No relevant conflicts of interest to declare.